Articles Posted in Dangerous Products

On August 28 of this year, certain electric motors found in Air Vent’s gable- and roof-mounted attic fans sold from August 2003-December 2013 were recalled using the fast track method. Around 2.9 million electric motors are affected by the recall. The reason for the recall is that the motor’s safety cutoff could present a chance of short circuit and fire danger while the attic fan is being used. If you or a loved one was injured or died as a result of a fire involving your attic fan, you should call the seasoned Chicago-based product liability lawyers of Moll Law Group about whether you have grounds to sue for damages. Billions have been recovered in product liability cases around the country with which we’ve been involved.

Call Moll Law Group About an Attic Fan Lawsuit

The attic fans with affected motors, distributed by Air Vent, were sold between August 2003-December 2013 at Lowe’s, Beacon, ABC Supply, and other stores and wholesalers around the country. They sold for around $74 and $92.

The attic fan model numbers impacted by the recall are DOW-136-0-34-XIN, DOW-136-0-26-XIN, DOW-136-0-40-XIN, DOW-136-0-40-XIN-3/4”, and D-RE-PSC-127/20-4P1SP. The affected motors have a special vent pattern on the motor end bells. There have been 159 reports of fire or burning incidents related to the recalled attic fan motors, but so far, there haven’t been reports of injuries

Continue reading →

A new danger has emerged in vape shops and at gas stations and corner stores. Health officials warn that a concentrated kratom byproduct called 7-OH is being produced and marketed in ways that appeal to kids, and can be bought easily, even though it is believed to have effects and impacts similar to those of opioids. The 7-OH products are available to consumers in a range of forms and packages such as candy, fruit-flavored gummies, ice cream cones, drink mixes and shots, and tablets. Officials worry these products may represent the next stage of the opioid crisis. The FDA has  taken steps to get 7-OH restricted. If you or your child was harmed by 7-OH, you should call the seasoned Chicago-based product liability lawyers of Moll Law Group. Billions have been recovered in product liability lawsuits around the country with which we’ve been involved.

Call Moll Law Group About Your Potential Claim

On July 29, the United States Department of Health and Human Services (HHS) let consumers know that the U.S. Food and Drug Administration (FDA) is taking steps to try to stop the availability of 7-OH. There’s been a recommendation to restrict some of the products that contain 7-OH under the Controlled Substances Act, for instance. Further, the FDA has provided consumers with educational materials, health care providers with a letter, and a scientific assessment that indicates people can develop opioid addiction when they use 7-OH products repeatedly or over a long time. The FDA has also sent warning letters to various businesses for illegal marketing of products containing the addictive substance.

7-OH, which appeared in products starting around 2023, is also referred to as 7-hydroxymitragynine, 7-hydroxy, 7-OHMG, 7-HMG, and 7. It is one of two psychoactive components that occurs naturally in kratom, which is a plant whose leaves were sold for medicinal and recreational purposes throughout the 2000s. There are only small quantities of 7-OH in kratom, but the products that are sold in cape shops have significant quantities of 7-OH; it’s believed that synthetic steps are taken to change another psychoactive component of kratom, one that exists in greater quantities, into 7-OH.

Continue reading →

The Trump Administration has proposed elimination of the Consumer Product Safety Commission (CPSC), a bipartisan independent agency created by Congress that handles numerous product safety questions. An elimination of the agency would take crucial data-driven safety rules that protect people around the country from dangerous and defective products and immediately leave those rules vulnerable to political aims. The CPSC’s own 2026 budget request to Congress was the vehicle for the proposal of both agency elimination and an alarming reduction in consumer safety funding and staffing. This budget request, as well as an earlier leak of Administration documents that revealed a plan to get rid of the CPSC, have been strongly condemned by the Consumer Federation of America and other groups. There is still recourse if you or a loved one was injured by a defective or dangerous product. You should consult the seasoned product liability lawyers of Moll Law Group to determine whether you have a viable claim. Billions have been recovered in lawsuits with which we’ve been involved.

Talk to Moll Law Group About Your Defective Product Claim

The CPSC budget request proposes that CPSC functions be transferred to the Department of Health and Human Services (HHS). Meanwhile, the HHS is also experiencing a dramatic reduction in both funding and workforce. There have been layoffs, grant cancellations, and disruptions to public health programs around the country. In its criticism of the budget request for elimination, the Consumer Federation stated that it was fantastical to think that a new assistant secretary position could effectively utilize HHS administrative and support functions in the face of HHS’s huge budget cuts. The budget request, it says, will impair the ability to discover, respond to, and ultimately stop dangerous products from entering homes.

There are also 121 consumer advocacy groups that have called on Congress to reject the plan to collapse CPSC into HHS on the grounds that moving the agency could delay and weaken oversight, including the taking of important safety actions around dangerous products. The groups have asked Congress to maintain CPSC’s independence in the interests of household safety, and they’ve also asked Congress to fully fund the original fiscal year 2026 budget request from CPSC rather than follow the transfer plan. With the funds from the original budget request, the CPSC could conduct detailed investigations of emerging dangers, inform the public more clearly about safety problems, modernize its outdated technologies, stop dangerous items at ports of entry, and improve enforcement of product safety laws.

Continue reading →

Recently, a medication for sickle cell disease, Oxbryta, was voluntarily recalled because it can cause complications and death. Litigation has begun against Pfizer Inc. and its subsidiary Global Therapeutics. One plaintiff, a patient who underwent treatment, has alleged that the companies should have known that administration of the sickle cell treatment could result in a patient’s death. According to that plaintiff, he suffered a higher rate of vaso-occlusive crisis after he used the medication. Pfizer denies that it acted irresponsibly. If you were harmed by Oxbryta, give the seasoned Chicago-based dangerous drug lawyers of Moll Law Group a call.

Call Moll Law Group About Your Oxbryta Claim

Oxbryta is a drug that was meant to alleviate sick cell disease symptoms. It was formulated to prevent hemoglobin polymerization; this, in turn, stops the sickling of red blood cells and improving the ability for hemoglobin to be oxygenated. In 2019, the Food and Drug Administration (FDA) accelerated its approval for those patients who are at least 12-years-old. In 2021, the FDA approved the drug for children with the minimum age for use being age 4. Unfortunately, once the drug was used in the real world, certain side effects were dire. One of the complications that arose in connection with the drug were vaso-occlusive crises, painful incidents where the sickled blood cells obstruct the flow of blood through a patient’s body. Some patients died as a result of these complications.

Pfizer recalled the drug across the world in September 2024, due to this real-world data that indicated Oxbryta’s risks are greater than its potential benefits. Patients and family members brought many lawsuits against Pfizer, and many of these claimed that Pfizer and its subsidiary had failed to provide adequate warnings as to these risks and complications. In plain terms, they are arguing that the company didn’t let them know about the risk of suffering vaso-occlusive crises and death and this prevented doctors and patients from making informed decisions about whether or not to take the drug.

Continue reading →